Overview
Retatrutide (LY3437943) 20mg Injection Pen is a next-generation triple incretin receptor agonist studied for transformative effects on fat loss, body composition, and metabolic health. Simultaneously activating GLP-1, GIP, and glucagon receptors, Retatrutide represents the leading edge of metabolic peptide research — now delivered in an advanced pre-filled injection pen format for unmatched convenience and dose precision.
This advanced-formula pen delivers 20mg of high-purity Retatrutide, HPLC-verified at premium research-grade purity. The pen system is engineered for painless subcutaneous administration with an ultra-fine needle, dial-in dose selection, and simple one-hand operation — no reconstitution, no vial handling, no measurement variance between doses.
Key Benefits
- Advanced pen formulation — pre-filled, HPLC-verified premium purity, ready to use out of the box with no reconstitution required
- Painless injection experience — ultra-fine needle and smooth-action mechanism minimize discomfort, even for weekly protocols
- Accurate, repeatable dosing — dial-in dose selector delivers the exact amount every time, eliminating syringe measurement errors
- Effortless handling — one-hand operation, intuitive design; suitable for researchers new to peptide administration
- Convenient storage & travel — compact pen body, discreet, and stable under standard refrigeration
- Triple receptor mechanism — GLP-1 + GIP + glucagon agonism for comprehensive metabolic effects
- Superior fat loss research profile — showing greater effects than dual-agonist peptides in comparative trials
- Lean mass preservation — studied for favorable body composition outcomes vs. total mass loss
Popular Use Cases
- Body recomposition research — studied for pronounced fat mass reduction with lean mass preservation
- Metabolic health optimization — insulin sensitivity, glucose homeostasis, and lipid profile modulation
- Obesity research — leading candidate in next-generation metabolic peptide studies
- Long-duration protocols — weekly-dose pen format makes months-long studies significantly easier to maintain
- Comparative metabolic research — benchmarked against tirzepatide and semaglutide
Who Commonly Uses Retratutide
Research interest in the Retatrutide injection pen spans metabolic researchers, endocrinology labs, obesity researchers, and body composition scientists. The pen’s painless, one-hand operation is a major draw for weekly-dose protocols where user experience matters over long study durations. Wellness-oriented individuals in expat and international communities in Vietnam and Southeast Asia have shown growing interest in this advanced pen format as part of comprehensive metabolic optimization research — precisely because it removes the technical barriers and dosing errors associated with traditional reconstitution.
Product Details
- Peptide: Retatrutide (LY3437943, GLP-1/GIP/Glucagon triple agonist)
- Peptide Content: 20mg per injection pen
- Format: Pre-filled multi-dose injection pen with dial-in dose selector
- Needle: Ultra-fine included — designed for painless subcutaneous administration
- Purity: Premium research-grade (HPLC verified)
- Storage (unopened): 2–8°C refrigerated, away from light
- Storage (in use): 2–8°C, use within 28 days of first activation
- Research Use: For laboratory and research purposes only
Storage & Handling
Store the unopened Retatrutide injection pen refrigerated at 2–8°C and protected from direct light. Avoid freeze-thaw cycles, which can degrade peptide integrity. Once the pen is activated for first use, keep it refrigerated between doses and use within 28 days for optimal stability. The sealed pen body protects the formulation from air and light between doses, extending working stability compared with open vials. The pen is designed for straightforward handling: dial the desired dose, attach the included ultra-fine needle, prime, and inject. No mixing, no drawing up, and no syringe calibration required.
Research & Scientific Interest
Retatrutide (LY3437943) is one of the most closely watched peptides in metabolic research. As a triple incretin agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, it has demonstrated superior effects on body weight, glycemic control, and hepatic fat reduction compared with dual-agonist peptides in preclinical and Phase 2 clinical trials. Key research areas include obesity, type 2 diabetes, non-alcoholic fatty liver disease (NAFLD), and cardiovascular metabolic health.
Delivering Retatrutide via an advanced pre-filled pen supports consistent, reproducible dosing across research sessions — a critical advantage for weekly-administration studies where dose precision directly affects metabolic and body composition outcomes.
Frequently Asked Questions
Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors — a step beyond semaglutide (GLP-1 only) and tirzepatide (GLP-1 + GIP). The added glucagon component enhances lipolysis and energy expenditure, producing more pronounced fat loss in research settings.
The pen format offers three major advantages over traditional vials: painless injection with an ultra-fine needle, precise dial-in dosing that eliminates syringe measurement error, and easy one-hand handling. It is also more convenient to store and travel with, making long-duration weekly protocols significantly easier to maintain.
Phase 2 clinical trials have shown some of the most pronounced body weight reductions observed for any single metabolic peptide, along with significant improvements in glycemic control and hepatic fat.
Simultaneous activation of GLP-1, GIP, and glucagon receptors produces complementary effects: appetite suppression, enhanced insulin sensitivity, increased energy expenditure, and lipolysis — an approach unique among current metabolic peptides.
Research suggests Retatrutide may support favorable body composition outcomes, with significant fat mass reduction while lean mass is relatively preserved compared with total mass loss protocols.
No. The Retatrutide injection pen ships pre-filled with an advanced, stabilized formulation. There is no need for bacteriostatic water or manual mixing — simply attach the included needle, dial the dose, and administer.
Store the pen refrigerated at 2–8°C, away from direct light. Once activated for first use, continue refrigerated storage between doses and use within 28 days.
In research contexts, Retatrutide is sometimes referenced alongside other metabolic peptides. Any research stacking protocol should be designed by qualified researchers familiar with each peptide’s mechanisms.
Gastrointestinal effects (nausea, diarrhea, vomiting) have been the most commonly reported in clinical trials — typical of GLP-1-based therapies and generally dose-dependent.
Yes. LY3437943 is the developmental code name for Retatrutide used in Eli Lilly’s research pipeline.
Glucagon receptor activation increases energy expenditure, promotes lipolysis, and enhances hepatic fat oxidation — mechanisms that complement GLP-1/GIP-mediated appetite suppression.
Retatrutide combines the most advanced triple-agonist mechanism with premium HPLC-verified purity — now in an advanced pre-filled pen delivery system for maximum research reproducibility.
Yes. Research has demonstrated improvements in insulin sensitivity, HbA1c, liver fat, blood pressure, and lipid markers.
Retatrutide is in advanced-stage clinical trials as of publication, positioning it as one of the most anticipated next-generation metabolic peptides.
Yes. H&J Pharma offers same-day shipping with next-day delivery across Vietnam.
Research References
- Jastreboff AM, et al. “Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.” New England Journal of Medicine. 2023.
- Rosenstock J, et al. “Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial.” The Lancet. 2023.
- Coskun T, et al. “LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist, exerts robust and sustained anti-obesity efficacy in preclinical species.” Cell Metabolism. 2022.
Invest in Your Metabolic Future
The Retatrutide 20mg Injection Pen represents the most advanced metabolic research peptide currently available — combining a next-generation triple-agonist mechanism with the precision, convenience, and painless experience of an advanced pre-filled pen. H&J Pharma supplies this pen at pharmaceutical research grade, with HPLC-verified purity and cold-chain logistics ensuring product integrity from warehouse to delivery across Vietnam.
Sean –
Highly recommended!
I pulled the trigger on the Reta & the BPC/TB500 pen, and it has been amazing this far. Super fast delivery and great service.
Matthew –
Great! Fast shipping & great support!